Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: ulixertinib, ravoxertinib, asn007 +3 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 30 Parkinson's papers of 2,575 | 0.55 |
| pathways Reactome | 63 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 2926
Sealed predictions
- MAPK1 in dopamine neurons, braak+0.00 (p 1.000) → +0.05 (p 0.893)receipt 2932
Swarm cases
receipt 2932: MAPK1 in dopamine neurons, braak
- power
- full sample -0.01 (p 0.983, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.01 (p 0.976, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.04 (p 0.861, n 18). could be the mix.
- skeptic
- leave-one-out range -0.12 to +0.13, sign flips 7; without severely affected donors -0.01 (p 0.983, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAPK1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts